Sequential use of temsirolimus (TEM) in patients with metastatic renal cell carcinoma (mRCC): Safety and efficacy following failure of receptor tyrosine kinase inhibitor (TKI) treatment.
Phase of Trial: Phase IV
Latest Information Update: 05 Mar 2010
At a glance
- Drugs Temsirolimus (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 05 Mar 2010 Results were presented at the ASCO 2010 Genitourinary Cancers Symposium.
- 05 Mar 2010 New trial record